Secondary alcohols

Corsair Pharma, Inc. to Present at LifeSci Partners Annual Private Company Summer Symposium

Retrieved on: 
Thursday, July 15, 2021
Health sciences, Pharmacology, Orphan drugs, Prostaglandins, Secondary alcohols, Treprostinil, Health care, Pulmonary hypertension, Corsair, PAH, Transdermal patch

SOUTH SAN FRANCISCO, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- Corsair Pharma, Inc., a private biopharmaceutical company developing a transdermal treprostinil prodrug, today announced it will present at the LifeSci Partners Private Company Summer Symposium, to be held virtually July 21-23, 2021.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- Corsair Pharma, Inc., a private biopharmaceutical company developing a transdermal treprostinil prodrug, today announced it will present at the LifeSci Partners Private Company Summer Symposium, to be held virtually July 21-23, 2021.
  • Garrett Vygantas, Chief Business Officer of Corsair, will present an update on Corsairs lead product candidate, a prodrug of treprostinil delivered on a proprietary transdermal patch to treat Pulmonary Arterial Hypertension (PAH).
  • Corsair is scheduled to present Wednesday, July 21, 2021, at 2:30 pm Eastern Time.
  • Corsair is also exploring expansion opportunities into other forms of pulmonary hypertension.

Liquidia Announces FDA Acceptance of New Drug Application Resubmission for LIQ861 (treprostinil) Inhalation Powder

Retrieved on: 
Wednesday, June 2, 2021
Prostaglandins, Secondary alcohols, Orphan drugs, Chemical compounds, Treprostinil, Pulmonary hypertension, PAH, Chemistry, Organic compounds, United Therapeutics

MORRISVILLE, N.C., June 02, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for LIQ861 (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH).

Key Points: 
  • MORRISVILLE, N.C., June 02, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for LIQ861 (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH).
  • The FDA confirmed that the resubmission was a complete, class 2 response to the previous action letter issued on November 24, 2020.
  • Liquidia has completed an open-label, multi-center phase 3 clinical study of LIQ861 in patients diagnosed with PAH known as INSPIRE, or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil.
  • Liquidia Technologies is developing LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH).

Liquidia Corporation To Present At The Jefferies Virtual Healthcare Conference

Retrieved on: 
Wednesday, May 26, 2021
Orphan drugs, Prostaglandins, Secondary alcohols, Hypertension, Pulmonary hypertension, Treprostinil, PAH, ERT, Pulmonary artery, United Therapeutics

MORRISVILLE, N.C., May 26, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Damian deGoa, Chief Executive Officer of Liquidia, will provide an overview and update on the company's business during a fireside chat session at the Jefferies Virtual Healthcare Conference.

Key Points: 
  • MORRISVILLE, N.C., May 26, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Damian deGoa, Chief Executive Officer of Liquidia, will provide an overview and update on the company's business during a fireside chat session at the Jefferies Virtual Healthcare Conference.
  • Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT Technology.
  • The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC.
  • Liquidia Technologies is developing LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH).

Liquidia Announces Generic Treprostinil Injection Now Also Available for Subcutaneous Route of Administration

Retrieved on: 
Monday, May 24, 2021
Prostaglandins, Secondary alcohols, Treprostinil, Dosage forms, Subcutaneous injection, Injection, Health, Chemistry, Physical sciences

Both options for intravenous and SC administration of Sandoz generic Treprostinil Injection are now available at the same specialty pharmacy that dispenses the brand name medicine.

Key Points: 
  • Both options for intravenous and SC administration of Sandoz generic Treprostinil Injection are now available at the same specialty pharmacy that dispenses the brand name medicine.
  • Patients who need and depend on subcutaneously administered treprostinil will now, for the first time, have access to a lower cost generic treprostinil.
  • The cartridges required to operate the CADD-MS 3 pump were not available to patients using generic Treprostinil Injection due to restrictions imposed by other companies.
  • CADD-MS 3 is a registered trademark of Smiths Medical ASD, Inc.
    Treprostinil Injection is the first-to-file, fully substitutable generic treprostinil for parenteral administration.

Sandoz announces generic Treprostinil Injection now also available for subcutaneous route of administration to treat PAH patients in US

Retrieved on: 
Monday, May 24, 2021
Prostaglandins, Secondary alcohols, Health sciences, Treprostinil, Health care, Health, United Therapeutics, Pulmonary hypertension, Subcutaneous, Generic drug

PRINCETON, N.J., May 24, 2021 /PRNewswire/ --Sandoz today announced Treprostinil Injection, a generic Remodulin, is now also available for subcutaneous ("SC") administration to treat patients diagnosed with pulmonary arterial hypertension ("PAH").

Key Points: 
  • PRINCETON, N.J., May 24, 2021 /PRNewswire/ --Sandoz today announced Treprostinil Injection, a generic Remodulin, is now also available for subcutaneous ("SC") administration to treat patients diagnosed with pulmonary arterial hypertension ("PAH").
  • Sandoz Treprostinil Injection was the first fully-substitutable AP rated generic version of Remodulin* (treprostinil) Injection, sold by United Therapeutics Corporation.
  • The cartridges required to operate the CADD-MS 3 pump, were not available to patients using generic Treprostinil Injection due to restrictions imposed by other companies.
  • Patients who need and depend on SC administered treprostinil will now, for the first time, have access to a lower cost generic treprostinil.

Liquidia Resubmits New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension

Retrieved on: 
Monday, May 10, 2021
Orphan drugs, Prostaglandins, Secondary alcohols, Hypertension, Pulmonary hypertension, Treprostinil, PAH, United Therapeutics

b'MORRISVILLE, N.C., May 10, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that on May 7, 2021, it resubmitted its New Drug Application (NDA) for LIQ861 for the treatment of pulmonary arterial hypertension (PAH).

Key Points: 
  • b'MORRISVILLE, N.C., May 10, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that on May 7, 2021, it resubmitted its New Drug Application (NDA) for LIQ861 for the treatment of pulmonary arterial hypertension (PAH).
  • No additional data from clinical trials or studies related to toxicology or clinical pharmacology was required.
  • The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC.
  • Liquidia Technologies is developing LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of PAH.

New Real-World Observational Analysis of UPTRAVI® (selexipag) Underscores the Importance of Risk Assessment for Treating Pulmonary Arterial Hypertension (PAH) Patients

Retrieved on: 
Tuesday, April 6, 2021
Chemistry, Chemical compounds, Organic compounds, Carboxylic acids, Hypertension, Prostaglandins, Secondary alcohols, Sulfonamides, Pulmonary hypertension, Selexipag, Prostacyclin, Riociguat

In the pivotal GRIPHON trial, UPTRAVI was proven to reduce the risk of disease progression by 40%.

Key Points: 
  • In the pivotal GRIPHON trial, UPTRAVI was proven to reduce the risk of disease progression by 40%.
  • SPHERE enrolled patients who were either newly initiated on UPTRAVI (60 days before enrollment) or previously received UPTRAVI with documentation of dose titration at study enrollment.
  • The efficacy of UPTRAVI in PAH was established in GRIPHON (Prostacyclin [PGI2] Receptor agonist In Pulmonary arterial HypertensiON), the largest randomized, controlled trial ever conducted in PAH patients.
  • Hyperthyroidism was observed in 1% (n=8) of patients on UPTRAVI and in none of the patients on placebo.

Liquidia Announces Generic Treprostinil Injection Will Be Available for Subcutaneous Route of Administration

Retrieved on: 
Tuesday, March 30, 2021
Prostaglandins, Secondary alcohols, Treprostinil, Routes of administration, Injection, Subcutaneous injection, Subcutaneous, Health, Chemistry, Physical sciences

We worked hard to overcome this obstacle, and we can now offer generic Treprostinil Injection to more than double the number of PAH patients.

Key Points: 
  • We worked hard to overcome this obstacle, and we can now offer generic Treprostinil Injection to more than double the number of PAH patients.
  • Since commercial launch two years ago, Treprostinil Injection has only been used for intravenous administration.
  • The cartridges required to operate the only subcutaneous pump that could deliver treprostinil injection (CADD-MS 3) were not made available to patients using generic treprostinil injection.
  • CADD-MS 3 is a registered trademark of Smiths Medical ASD, Inc.
    Treprostinil Injection is the first-to-file, fully substitutable generic treprostinil for parenteral administration.

Outlook on the Natural and Synthetic Lutein Global Market to 2027 - Key Drivers, Restraints and Opportunities

Retrieved on: 
Friday, March 5, 2021
Chemical compounds, Carotenoids, Food colorings, Secondary alcohols, Lutein, Chemical substances

Global Natural and Synthetic Lutein Market Value, Market Share, and Forecast to 2027

Key Points: 
  • Global Natural and Synthetic Lutein Market Value, Market Share, and Forecast to 2027
    3.1 Global Natural and Synthetic Lutein Market Overview, 2020
    3.2 Global Natural and Synthetic Lutein Market Revenue and Forecast, 2021-2027 (US$ Million)
    3.3 Global Natural and Synthetic Lutein Market Size and Share Outlook by Type, 2021-2027
    3.4 Global Natural and Synthetic Lutein Market Size and Share Outlook by End-User, 2021-2027
    3.5 Global Natural and Synthetic Lutein Market Size and Share Outlook by Region, 2021-2027
    4.
  • Asia Pacific Natural and Synthetic Lutein Market Value, Market Share and Forecast to 2027
    4.1 Asia Pacific Natural and Synthetic Lutein Market Overview, 2020
    4.2 Asia Pacific Natural and Synthetic Lutein Market Revenue and Forecast, 2021-2027 (US$ Million)
    4.3 Asia Pacific Natural and Synthetic Lutein Market Size and Share Outlook by Type, 2021-2027
    4.4 Asia Pacific Natural and Synthetic Lutein Market Size and Share Outlook by End-User, 2021-2027
    4.5 Asia Pacific Natural and Synthetic Lutein Market Size and Share Outlook by Country, 2021-2027
    5.
  • Europe Natural and Synthetic Lutein Market Value, Market Share, and Forecast to 2027
    5.1 Europe Natural and Synthetic Lutein Market Overview, 2020
    5.2 Europe Natural and Synthetic Lutein Market Revenue and Forecast, 2021-2027 (US$ Million)
    5.3 Europe Natural and Synthetic Lutein Market Size and Share Outlook by Type, 2021-2027
    5.4 Europe Natural and Synthetic Lutein Market Size and Share Outlook by End-User, 2021-2027
    5.5 Europe Natural and Synthetic Lutein Market Size and Share Outlook by Country, 2021-2027
    6.
  • North America Natural and Synthetic Lutein Market Value, Market Share and Forecast to 2027
    6.1 North America Natural and Synthetic Lutein Market Overview, 2020
    6.2 North America Natural and Synthetic Lutein Market Revenue and Forecast, 2021-2027 (US$ Million)
    6.3 North America Natural and Synthetic Lutein Market Size and Share Outlook by Type, 2021-2027
    6.4 North America Natural and Synthetic Lutein Market Size and Share Outlook by End-User, 2021-2027
    6.5 North America Natural and Synthetic Lutein Market Size and Share Outlook by Country, 2021-2027
    7.

Worldwide Natural and Synthetic Lutein Industry to 2027 - by Type, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 3, 2021
Food, Beverage, Retail, Carotenoids, Chemical compounds, Food colorings, Secondary alcohols, Lutein, Chemical substances

The Natural and Synthetic Lutein report computes the 2020 market value in revenue terms based on the average Natural and Synthetic Lutein prices and sales/revenue models of key companies operating in the Natural and Synthetic Lutein Market Industry.

Key Points: 
  • The Natural and Synthetic Lutein report computes the 2020 market value in revenue terms based on the average Natural and Synthetic Lutein prices and sales/revenue models of key companies operating in the Natural and Synthetic Lutein Market Industry.
  • Global Natural and Synthetic Lutein Market Industry size, 2020-2027
    Types of Natural and Synthetic Lutein, 2020-2027
    Natural and Synthetic Lutein applications and end-user verticals market size, 2020-2027
    Natural and Synthetic Lutein Market size across countries, 2020-2027
    5 leading companies in the industry - overview, key strategies, financials, and products
    2.
  • Natural and Synthetic Lutein Market Latest Trends, Drivers and Challenges, 2020 -2027
    2.3 Natural and Synthetic Lutein Market Insights, 2021-2027
    2.3.1 Leading Natural and Synthetic Lutein types, 2021-2027
    2.3.2 Leading Natural and Synthetic Lutein End-User industries, 2021-2027
    2.3.3 Fast-Growing countries for Natural and Synthetic Lutein sales, 2021-2027
    3.
  • Global Natural and Synthetic Lutein Market Value, Market Share, and Forecast to 2027
    3.1 Global Natural and Synthetic Lutein Market Overview, 2020
    3.2 Global Natural and Synthetic Lutein Market Revenue and Forecast, 2021-2027 (US$ Million)
    3.3 Global Natural and Synthetic Lutein Market Size and Share Outlook by Type, 2021-2027
    3.4 Global Natural and Synthetic Lutein Market Size and Share Outlook by End-User, 2021-2027
    3.5 Global Natural and Synthetic Lutein Market Size and Share Outlook by Region, 2021-2027
    4.